Prognostic significance of [18F]FDG PET metabolic parameters in adults and children with soft-tissue sarcoma: a meta-analysis

IF 2.3 4区医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Clinical and Translational Imaging Pub Date : 2024-02-27 DOI:10.1007/s40336-024-00620-9

M. Ya. Yadgarov, L. B. Berikashvili, E. S. Rakova, D. Yu. Kachanov, Yu. N. Likar

{"title":"Prognostic significance of [18F]FDG PET metabolic parameters in adults and children with soft-tissue sarcoma: a meta-analysis","authors":"M. Ya. Yadgarov, L. B. Berikashvili, E. S. Rakova, D. Yu. Kachanov, Yu. N. Likar","doi":"10.1007/s40336-024-00620-9","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>Soft-tissue sarcomas (STS) represent a diverse group of rare malignancies, underscoring the need for precise risk stratification. [<sup>18</sup>F]fluoro‑2‑deoxy‑2‑d‑glucose positron emission tomography ([<sup>18</sup>F]FDG PET) imaging parameters have been proposed as potential prognostic indicators in several cancer types, yet their significance in STS remains under investigation. This study aimed to synthesize the available evidence and assess the prognostic value of these parameters.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>A systematic review and meta-analysis was conducted, employing a comprehensive literature search across multiple databases. The prognostic value of [<sup>18</sup>F]FDG PET parameters, including pre- and post- treatment standardized uptake values (SUV1, SUV2), pretreatment metabolic tumor volume (MTV1) and total lesion glycolysis (TLG1) on event-free survival (EFS) and overall survival (OS) in patients with STS was examined.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Thirty-one studies with 1,932 patients were identified. The analyses demonstrated significant relationships between higher SUV1 (hazard ratio, HR 1.68 for EFS and 3.07 for OS, <i>p</i> < 0.001), SUV2 (HR 3.13 for EFS and 2.09 for OS, <i>p</i> < 0.001 and <i>p</i> = 0.001 respectively), MTV1 (HR 2.29 for EFS and 3.05 for OS, <i>p</i> = 0.011 and <i>p</i> < 0.001 respectively), TLG1 (HR 2.85 for EFS and 3.23 for OS, <i>p</i> = 0.032 and <i>p</i> = 0.002 respectively) and poorer survival outcomes. However, the association of these parameters with survival outcomes was non-significant in pediatric patients.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>This study suggests that [<sup>18</sup>F]FDG PET parameters could serve as important prognostic markers in adults with STS, but not in pediatric patients. Future studies with larger cohorts and uniform methodologies are critical to confirm and build upon these findings.</p>","PeriodicalId":48600,"journal":{"name":"Clinical and Translational Imaging","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2024-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Imaging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40336-024-00620-9","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Soft-tissue sarcomas (STS) represent a diverse group of rare malignancies, underscoring the need for precise risk stratification. [¹⁸F]fluoro‑2‑deoxy‑2‑d‑glucose positron emission tomography ([¹⁸F]FDG PET) imaging parameters have been proposed as potential prognostic indicators in several cancer types, yet their significance in STS remains under investigation. This study aimed to synthesize the available evidence and assess the prognostic value of these parameters.

Methods

A systematic review and meta-analysis was conducted, employing a comprehensive literature search across multiple databases. The prognostic value of [¹⁸F]FDG PET parameters, including pre- and post- treatment standardized uptake values (SUV1, SUV2), pretreatment metabolic tumor volume (MTV1) and total lesion glycolysis (TLG1) on event-free survival (EFS) and overall survival (OS) in patients with STS was examined.

Results

Thirty-one studies with 1,932 patients were identified. The analyses demonstrated significant relationships between higher SUV1 (hazard ratio, HR 1.68 for EFS and 3.07 for OS, p < 0.001), SUV2 (HR 3.13 for EFS and 2.09 for OS, p < 0.001 and p = 0.001 respectively), MTV1 (HR 2.29 for EFS and 3.05 for OS, p = 0.011 and p < 0.001 respectively), TLG1 (HR 2.85 for EFS and 3.23 for OS, p = 0.032 and p = 0.002 respectively) and poorer survival outcomes. However, the association of these parameters with survival outcomes was non-significant in pediatric patients.

Conclusion

This study suggests that [¹⁸F]FDG PET parameters could serve as important prognostic markers in adults with STS, but not in pediatric patients. Future studies with larger cohorts and uniform methodologies are critical to confirm and build upon these findings.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

成人和儿童软组织肉瘤患者[18F]FDG PET代谢参数的预后意义：荟萃分析

背景软组织肉瘤（STS）是一种多种多样的罕见恶性肿瘤，因此需要进行精确的风险分层。[18F]氟-2-脱氧-2-d-葡萄糖正电子发射断层扫描（[18F]FDG PET）成像参数被认为是几种癌症类型的潜在预后指标，但它们在 STS 中的意义仍有待研究。本研究旨在综合现有证据，评估这些参数的预后价值。方法通过多个数据库的全面文献检索，进行了系统综述和荟萃分析。研究了[18F]FDG PET参数的预后价值，包括治疗前后的标准化摄取值（SUV1、SUV2）、治疗前代谢肿瘤体积（MTV1）和总病变糖酵解（TLG1）对STS患者无事件生存期（EFS）和总生存期（OS）的影响。分析表明，较高的 SUV1（危险比，EFS 为 HR 1.68，OS 为 3.07，p < 0.001）、SUV2（EFS 为 HR 3.13，OS 为 2.09，p < 0.001 和 p = 0.001）、MTV1（EFS HR 2.29，OS HR 3.05，分别为 p = 0.011 和 p < 0.001）、TLG1（EFS HR 2.85，OS HR 3.23，分别为 p = 0.032 和 p = 0.002）与较差的生存结局有关。结论本研究表明，[18F]FDG PET参数可作为成人STS患者的重要预后标志物，但在儿童患者中并不适用。未来的研究需要更大的队列和统一的方法来证实和巩固这些发现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Clinical and Translational Imaging Medicine-Radiology, Nuclear Medicine and Imaging

CiteScore

3.60

自引率

4.80%

发文量

期刊介绍： Clinical and Translational Imaging is an international journal that publishes timely, up-to-date summaries on clinical practice and translational research and clinical applications of approved and experimental radiopharmaceuticals for diagnostic and therapeutic purposes. Coverage includes such topics as advanced preclinical evidence in the fields of physics, dosimetry, radiation biology and radiopharmacy with relevance to applications in human subjects. The journal benefits a readership of nuclear medicine practitioners and allied professionals involved in molecular imaging and therapy.